Feedback

Recent advances in the development and application of colorectal cancer mouse models

Affiliation
Nanxiang Branch of Ruijin Hospital ,Shanghai Jiao Tong University School of Medicine ,Shanghai ,China
Wang, Ting;
Affiliation
The Second Clinical Medical College of Henan University of Chinese Medicine ,Zhengzhou ,China
Chen, Zhen;
Affiliation
Jiading Branch of Shanghai General Hospital ,Shanghai Jiao Tong University School of Medicine ,Shanghai ,China
Zhang, Yuli;
Affiliation
Nanxiang Branch of Ruijin Hospital ,Shanghai Jiao Tong University School of Medicine ,Shanghai ,China
Liu, Min;
Affiliation
Jiading Branch of Shanghai General Hospital ,Shanghai Jiao Tong University School of Medicine ,Shanghai ,China
Sui, Hua;
Affiliation
Nanxiang Branch of Ruijin Hospital ,Shanghai Jiao Tong University School of Medicine ,Shanghai ,China
Tang, Qingfeng

Colorectal cancer (CRC) remains a significant global health challenge, necessitating the development of reliable preclinical models to advance mechanistic understanding and therapeutic innovation. This review comprehensively examines the diverse spectrum of rodent models employed in CRC research, focusing on their unique characteristics, applications, and translational relevance. We systematically evaluate conventional models, including carcinogen-induced models and genetically engineered mouse models (GEMMs), which have been instrumental in elucidating tumorigenic pathways and genetic drivers. Furthermore, we highlight the emergence of patient-derived xenografts (PDX) as a transformative tool for recapitulating tumor heterogeneity and predicting clinical responses. The review also explores metastatic models, which are critical for studying advanced disease, and spontaneous models that mimic natural tumor progression. Additionally, we discuss the growing utility of composite animal models, which integrate multiple methodologies to better reflect the complexity of human CRC. By comparing the strengths and limitations of each model system, this review provides a framework for selecting appropriate models based on specific research objectives. Collectively, these preclinical platforms have significantly advanced our understanding of CRC biology and continue to drive the development of targeted therapies and personalized treatment strategies.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2025 Wang, Chen, Zhang, Liu, Sui and Tang.

Use and reproduction: